Federico Augustovski - Institute for Clinical Effectiveness and Health Policy (IECS-CONICET), Buenos Aires, Argentina
Lisandro D. Colantonio - University of Alabama at Birmingham, Birmingham, AL, USA
Julieta Galante - Cardiff University, Cardiff, UK
Ariel Bardach - Institute for Clinical Effectiveness and Health Policy (IECS-CONICET), Buenos Aires, Argentina
Joaquín E. Caporale - Institute for Clinical Effectiveness and Health Policy (IECS-CONICET), Buenos Aires, Argentina
Víctor Zárate - Facultad de Medicina, Universidad San Sebastian, Santiago, Chile
Ling Hsiang Chuang - Pharmerit, Rotterdam, The Netherlands
Andres Pichon-Riviere - Institute for Clinical Effectiveness and Health Policy (IECS-CONICET), Buenos Aires, Argentina
Paul Kind - University of Leeds, Leeds, UK

Background The measurement of health benefits is a key issue in health economic evaluations. There is very scarce empirical literature exploring the differences of using quality-adjusted life years (QALYs) or disability-adjusted life years (DALYs) as benefit metrics and their potential impact in decision-making.   Methods Two previously published models delivering outputs in QALYs, were adapted to estimate DALYs: a Markov model for human papilloma virus (HPV) vaccination, and a pneumococcal vaccination deterministic model (PNEUMO). Argentina, Chile, and the United Kingdom studies were used, where local EQ-۵D social value weights were available to provide local QALY weights. A primary study with descriptive vignettes was done (n = ۷۳) to obtain EQ-۵D data for all health states included in both models. Several scenario analyses were carried-out to evaluate the relative importance of using different metrics (DALYS or QALYs) to estimate health benefits on these economic evaluations.   Results QALY gains were larger than DALYs avoided in all countries for HPV, leading to more favorable decisions using the former. With discounting and age-weighting – scenario with greatest differences in all countries – incremental DALYs avoided represented the ۷۵%, ۶۸%, and ۴۳% of the QALYs gained in Argentina, Chile, and United Kingdom respectively. Differences using QALYs or DALYs were less consistent and sometimes in the opposite direction for PNEUMO. These differences, similar to other widely used assumptions, could directly influence decision-making using usual gross domestic products (GDPs) per capita per DALY or QALY thresholds.   Conclusion We did not find evidence that contradicts current practice of many researchers and decision-makers of using QALYs or DALYs interchangeably. Differences attributed to the choice of metric could influence final decisions, but similarly to other frequently used assumptions.

Quality-Adjusted Life Year (QALY), Disability-Adjusted Life Year (DALY), Health Benefit Measure, Economic Evaluation